1 Ocak 2022 Dergi makalesi Açık Erişim

Ahan, Recep E.; Hanifehnezhad, Alireza; Kehribar, Ebru S.; Oguzoglu, Tuba C.; Foldes, Katalin; Ozcelik, Cemile E.; Filazi, Nazlican; Oztop, Sidika; Palaz, Fahreddin; Onder, Sevgen; Bozkurt, Eray U.; Ergunay, Koray; Ozkul, Aykut; Seker, Urartu Ozgur Safak

MARC21 XML

<?xml version='1.0' encoding='UTF-8'?>
<record xmlns="http://www.loc.gov/MARC21/slim">
  <leader>00000nam##2200000uu#4500</leader>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Hanifehnezhad, Alireza</subfield>
    <subfield code="u">Ankara Univ, Fac Vet Med, Dept Virol, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Kehribar, Ebru S.</subfield>
    <subfield code="u">Bilkent Univ, UNAM Inst Mat Sci &amp; Nanotechnol, TR-06800 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Oguzoglu, Tuba C.</subfield>
    <subfield code="u">Ankara Univ, Fac Vet Med, Dept Virol, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Foldes, Katalin</subfield>
    <subfield code="u">Ankara Univ, Fac Vet Med, Dept Virol, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ozcelik, Cemile E.</subfield>
    <subfield code="u">Bilkent Univ, UNAM Inst Mat Sci &amp; Nanotechnol, TR-06800 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Filazi, Nazlican</subfield>
    <subfield code="u">Ankara Univ, Fac Vet Med, Dept Virol, TR-06110 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Oztop, Sidika</subfield>
    <subfield code="u">Baskent Univ, Adana Dr Turgut Noyan Med &amp; Res Ctr, Dept Immunol, TR-01250 Adana, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Palaz, Fahreddin</subfield>
    <subfield code="u">Hacettepe Univ, Fac Med, TR-06230 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Onder, Sevgen</subfield>
    <subfield code="u">Hacettepe Univ, Fac Med, Dept Med Pathol, TR-06230 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Bozkurt, Eray U.</subfield>
    <subfield code="u">Bilkent Univ, UNAM Inst Mat Sci &amp; Nanotechnol, TR-06800 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ergunay, Koray</subfield>
    <subfield code="u">Hacettepe Univ, Fac Med, Dept Med Microbiol, Virol Unit, TR-06230 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Ozkul, Aykut</subfield>
  </datafield>
  <datafield tag="700" ind1=" " ind2=" ">
    <subfield code="a">Seker, Urartu Ozgur Safak</subfield>
    <subfield code="u">Bilkent Univ, UNAM Inst Mat Sci &amp; Nanotechnol, TR-06800 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="4">
    <subfield code="p">ACS INFECTIOUS DISEASES</subfield>
    <subfield code="v">8</subfield>
    <subfield code="n">7</subfield>
    <subfield code="c">1253-1264</subfield>
  </datafield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="540" ind1=" " ind2=" ">
    <subfield code="a">Creative Commons Attribution</subfield>
    <subfield code="u">http://www.opendefinition.org/licenses/cc-by</subfield>
  </datafield>
  <datafield tag="024" ind1=" " ind2=" ">
    <subfield code="a">10.1021/acsinfecdis.2c00006</subfield>
    <subfield code="2">doi</subfield>
  </datafield>
  <datafield tag="245" ind1=" " ind2=" ">
    <subfield code="a">A Highly Potent SARS-CoV-2 Blocking Lectin Protein</subfield>
  </datafield>
  <datafield tag="100" ind1=" " ind2=" ">
    <subfield code="a">Ahan, Recep E.</subfield>
    <subfield code="u">Bilkent Univ, UNAM Inst Mat Sci &amp; Nanotechnol, TR-06800 Ankara, Turkey</subfield>
  </datafield>
  <datafield tag="909" ind1="C" ind2="O">
    <subfield code="o">oai:aperta.ulakbim.gov.tr:253305</subfield>
    <subfield code="p">user-tubitak-destekli-proje-yayinlari</subfield>
  </datafield>
  <datafield tag="650" ind1="1" ind2="7">
    <subfield code="2">opendefinition.org</subfield>
    <subfield code="a">cc-by</subfield>
  </datafield>
  <datafield tag="260" ind1=" " ind2=" ">
    <subfield code="c">2022-01-01</subfield>
  </datafield>
  <datafield tag="856" ind1="4" ind2=" ">
    <subfield code="u">https://aperta.ulakbim.gov.trrecord/253305/files/bib-d2d91260-2af7-4593-a915-348c971b4f16.txt</subfield>
    <subfield code="z">md5:d1ded52d63303c05da4dc1c5ddfb2545</subfield>
    <subfield code="s">276</subfield>
  </datafield>
  <datafield tag="542" ind1=" " ind2=" ">
    <subfield code="l">open</subfield>
  </datafield>
  <controlfield tag="005">20230728185306.0</controlfield>
  <controlfield tag="001">253305</controlfield>
  <datafield tag="980" ind1=" " ind2=" ">
    <subfield code="a">publication</subfield>
    <subfield code="b">article</subfield>
  </datafield>
  <datafield tag="520" ind1=" " ind2=" ">
    <subfield code="a">The COVID-19 (coronavirus disease-19) pandemic affected more than 180 million people around the globe, causing more than five million deaths as of January 2022. SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the new coronavirus, has been identified as the primary cause of the infection. The number of vaccinated people is increasing; however, prophylactic drugs are highly demanded to ensure secure social contact. A number of drug molecules have been repurposed to fight against SARS-CoV-2, and some of them have been proven to be effective in preventing hospitalization or ICU admissions. Here, we demonstrated griffithsin (GRFT), a lectin protein, to block the entry of SARS-CoV-2 and its variants, Delta and Omicron, into the Vero E6 cell lines and IFNAR(-/-) mouse models by attaching to the spike protein of SARS-CoV-2. Given the current mutation frequency of SARS-CoV-2, we believe that GRFT protein-based drugs will have a high impact in preventing the transmission of both the Wuhan strain as well as any other emerging variants, including Delta and Omicron variants, causing the high-speed spread of COVID-19.</subfield>
  </datafield>
</record>